Nisa Leung
Managing Partner · Qiming Venture Partners
Check $2M–$50M
SERIES A
SERIES B_PLUS
Healthtech
Bio
AI
Investment thesis
Asia's leading healthcare investor. Deep expertise in biotech, medical devices, and digital health across China and Asia. Looks for scientific rigour, regulatory pathway clarity, and large unmet medical needs.
Communication style
Scientifically rigorous, data-driven, patient but thorough. Asks the questions a medical reviewer would ask.
Red flags
- •Weak or unreproducible science
- •No clear regulatory pathway
- •Small addressable patient population
- •No clinical advisory board
- •Overpromising timelines
Signature questions
- 1.Walk me through the clinical evidence.
- 2.What is your regulatory pathway and timeline?
- 3.What is the addressable patient population, and how did you size it?
- 4.Who is on your scientific advisory board?
- 5.What is the hardest regulatory hurdle you face?
Selected portfolio
Zai Lab
Belief BioMed
AI simulation. This persona is an AI-generated profile built from public data. Claim this profile to customize its accuracy. It does not represent any real individual's actual views or availability.